Trial reportJournal of proteomics2012
N-glycans in liver-secreted and immunoglogulin-derived protein fractions.
Trial report in Journal of proteomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease.Journal of proteomics · 2015Trial
- Large-scale serum N-glycomics tracks N-glycosylation dynamics in hepatocellular carcinoma progression and enables early diagnosis.Nature communications · 2026Article
- Secreted Glycoproteins That Regulate Synaptic Function: the Dispatchers in the Central Nervous System.Molecular neurobiology · 2024Review
- Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach.Advances in cancer research · 2023Review
- Defining the genetic control of human blood plasma N-glycome using genome-wide association study.Human molecular genetics · 2019Article
- Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.Journal of proteomics · 2017Article
- Study of Ethanol-Induced Golgi Disorganization Reveals the Potential Mechanism of Alcohol-Impaired N-Glycosylation.Alcoholism, clinical and experimental research · 2016Article
- Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV.Glycoconjugate journal · 2016Article
- Targeted methods for quantitative analysis of protein glycosylation.Proteomics. Clinical applications · 2015Review
- Detection of distinct glycosylation patterns on human γ-glutamyl transpeptidase 1 using antibody-lectin sandwich array (ALSA) technology.BMC biotechnology · 2014Article
- Quantification of fucosylated hemopexin and complement factor H in plasma of patients with liver disease.Analytical chemistry · 2014Article
- Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4.Journal of proteome research · 2014Article
- Changes in IgG and total plasma protein glycomes in acute systemic inflammation.Scientific reports · 2014Article
- Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.Molecular & cellular proteomics : MCP · 2013Article
- Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
N-glycosylation of proteins provides a rich source of information on liver disease progression because majority of serum glycoproteins, with the exception of immunoglobulins, are secreted by the liver. In this report, we present results of an optimized workflow for MALDI-TOF analysis of permethylated N-glycans detached from serum proteins and separated into liver secreted and immunoglobulin fractions. We have compared relative intensities of N-glycans in 23 healthy controls and 23 cirrhosis patients. We were able to detect 82 N-glycans associated primarily with liver secreted glycoproteins, 54 N-glycans in the protein G bound fraction and 52 N-glycans in the fraction bound to protein A. The N-glycan composition of the fractions differed substantially, independent of liver disease. The relative abundance of approximately 53% N-glycans in all fractions was significantly altered in the cirrhotic liver. The removal of immunoglobulins allowed detection of an increase in a series of high mannose and hybrid N-glycans associated with the liver secreted protein fraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.